Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

Novo Nordisk (NVO) is down -18.7%, or -$19.34 to $84.10. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

Novo Nordisk falls most on record after new weight drug disappoints Novo’s shares plunged as much as 27 per cent, and they’re now down 17 per cent for the year after a previous runup on the strength ...

This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a concerted push to bolster its pipeline beyond GLP-1 stalwarts Ozempic ...

COPENHAGEN, Dec 17 — Danish health authorities said on Monday they would ask the European Union’s drug regulator to review the findings of two Danish studies linking Novo Nordisk’s popular diabetes ...

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:NVO). And retail traders should know. We noticed this today when the trades showed up on publicly available ...